Creative Biolabs Announces Entry into AI-Powered Small Molecule Drug Design

Empowered by artificial intelligence technology, Creative Biolabs has established an innovative small molecule design and optimization service to deliver strategies and initiatives in an agile, rapid, and value-driven manner.

New York City, New York Dec 28, 2022 (Issuewire.com**)** - In the past years, interest in adding artificial intelligence (AI) technology in drug research and development has greatly surged. Industrial reports have noted that signs of the impact of AI in small-molecule drug discovery so far are related to greater efficiency and accelerated timelines in early-stage research.

Creative Biolabs is one of the companies that believe AI can fulfill its broader promise to increase clinical success rates and reduce drug R&D costs and has established the innovative small molecule design and optimization service to deliver strategies and initiatives in an agile, rapid, and value-driven manner.

The expert team has gathered published usage data from journals, partners, and patents to generate a large, customized proprietary data set. And based on the database, AI, big data, and machine learning are combined to enhance the ability to computationally generate, screen, and optimize hundreds of millions of therapeutic small molecules.

The whole service pipeline will be open and transparent to make sure the clients can get access to the results of every step.

After learning details on the unique needs of clients, an appointed manager will lead an expert team to (1) extract the information about small molecules, drug design, and target diseases; (2) train computers to find a perfect AI algorithm in large databases; (3) calculating and identifying the most suitable small molecule for further evaluating and testing; (4) use multiple molecule parameters to train and optimize the bespoke AI algorithm; (5) improve the structure and properties of targeted small molecules aided by the optimized AI algorithm; (6) assess the synthetic process and tractability of small molecules.

The service is of great flexibility that clients can either custom a complete project covering design, optimization, and manufacturing, or adapt a single process to their specific project.

“We’ve taken a deep dive into AI for drug discovery, and established a deep learning method for achieving target recognition of small molecules drugs. These deep learning models have been proved to successfully predict the activity and properties of various small molecules,” as introduced by a scientist at Creative Biolabs.

More information about AI solutions for drug development can be found at https://ai.creative-biolabs.com/.

About Creative Biolabs

Recognized as a reliable partner in antibody drug discovery and manufacturing serving academia and industry clients all over the world, Creative Biolabs has established an experimentally-certified AI platform, providing intelligent solutions to accelerate drug discovery and development covering antibody drugs and small molecule drugs. The AI solutions aim to help the pharma and biotechnology companies

cut costs, streamline the workflow, and save valuable research time.

Media Contact

Creative Biolabs

marketing@creative-biolabs.com

Source : Creative Biolabs

See on IssueWire